Dolly Parton COVID-19 Research Fund

Seed and Series A funding to three startups—HeroWear, IDBiologics and Virtuoso—rooted in research conducted at Vanderbilt University and Vanderbilt University Medical Center underscore a university-wide commitment to enhanced support for Vanderbilt’s most innovative faculty, students and alumni. Read More

A monoclonal antibody cocktail against the COVID-19 virus discovered at VUMC is the first non-vaccine modified to demonstrate the prevention of COVID-19 in a clinical trial of more than 5,000 participants. The antibody treatment could afford up to 12 months of protection from COVID-19, and preliminary laboratory findings also suggest that it can neutralize the delta variant. Read More

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read More

Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.  Read More

It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection. Read More